15 recruiting, 4 terminated, 2 unknown, 1 active not recruiting. 20 Phase 1, 9 Phase 2, 2 Early Phase 1.
Follow this condition Literature Review of Acute Myeloid Leukemia Refractory trials Research Report on Acute Myeloid Leukemia Refractory
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia CCTx-001 - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 / Phase 2 | Not yet recruiting | Advesya SAS | 143 | 2025-12-01 | 2025-09-18 |
| A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia Cytokine Induced Memory-Like Natural Killer Cells, Atezolizumb, CIML-NK cell therapy - Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 18 | 2025-05-30 | 2026-06-17 |
| Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS ARD103, Cyclophosphamide, Fludarabine - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 / Phase 2 | Recruiting | ARCE Therapeutics, Inc. | 49 | 2025-05-20 | 2025-12-10 |
| Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS) Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara) - Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory | Phase 2 | Recruiting | University of Illinois at Chicago | 38 | 2025-02-04 | 2026-06-26 |
| CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) CPI 613, Metformin, Blood draws - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2024-12-01 | 2024-09-19 | |
| Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] NP137, Azacitidine Injection, Venetoclax - Acute Myeloid Leukemia Refractory | Phase 1 / Phase 2 | Terminated | Centre Leon Berard | 1 | 2024-09-11 | 2025-02-20 |
| Master Framework For Relapse or Refractory Acute Myeloid Leukemia Registration into the STREAM platform - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Recruiting | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 4000 | 2024-06-28 | 2026-08-14 | |
| A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS APL-4098, Azacitidine and APL-4098, Azacitidine and Venetoclax and APL-4098 - Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia | Phase 1 | Recruiting | Apollo Therapeutics Ltd | 100 | 2024-06-04 | 2026-06-01 |
| Study of REM-422 in Patients With AML or Higher Risk MDS REM-422 - Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes | Phase 1 | Recruiting | Remix Therapeutics | 100 | 2024-04-26 | 2025-04-23 |
| CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia CB-012 - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Terminated | Caribou Biosciences, Inc. | 12 | 2024-02-08 | 2025-06-11 |
| Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion) Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123 - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Recruiting | AvenCell Europe GmbH | 37 | 2024-01-03 | 2026-09-24 |
| Off-the-shelf CD123 CAR-NK for R/R AML JD123 injection - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Early Phase 1 | Recruiting | Peking University People's Hospital | 12 | 2023-12-30 | 2025-03-11 |
| Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) anti Tim-3/CD123 CAR-T cell therapy - Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Xuzhou Medical University | 20 | 2023-11-04 | 2023-11-09 |
| A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia CD371-specific/YSNVz/I-18 CAR T cells - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 15 | 2023-09-01 | 2026-10-06 |
| Venetoclax to Augment Epigenetic Modification and Chemotherapy Venetoclax, Azacitadine, Vorinostat - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Recruiting | Medical College of Wisconsin | 40 | 2023-03-31 | 2026-01-12 |
| Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) Iadademstat, Gilteritinib Oral Tablet - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Active not recruiting | Oryzon Genomics S.A. | 50 | 2022-11-14 | 2026-08-24 |
| Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia CD123-CAR-NK cells - Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia Recurrent | Early Phase 1 | Unknown | Affiliated Hospital to Academy of Military Medical Sciences | 12 | 2022-10-01 | 2023-04-26 |
| A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Decitabine (in combination with BP1002) - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Recruiting | Bio-Path Holdings, Inc. | 48 | 2022-08-16 | 2025-03-10 |
| Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia Venetoclax, 6-mercaptopurine - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Recruiting | University Hospital, Antwerp | 10 | 2022-07-15 | 2022-08-18 |
| AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia AB8939, Venetoclax - Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | AB Science | 78 | 2022-06-01 | 2025-10-02 |
Showing 20 of 25. Sign in to see all of them.
Leukemia, Myeloid, Acute (24) · Recurrence (4) · Anemia, Refractory, with Excess of Blasts (2) · GATA2 Deficiency (2) · Myelodysplastic Syndromes (2) · Leukemia, Myeloid, Accelerated Phase (1) · Sarcoma, Myeloid (1)
Hematologic Diseases (24) · Hemic and Lymphatic Diseases (24) · Leukemia (24) · Leukemia, Myeloid (24) · Neoplasms (24) · Neoplasms by Histologic Type (24) · Bone Marrow Diseases (5) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Myelodysplastic Syndromes (3) · Anemia (2) · Anemia, Refractory (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2)
fludarabine (5) · venetoclax (5) · Cyclophosphamide (4) · Azacitidine (2) · Blood Specimen Collection (1) · Busulfan (1) · Cytarabine (1) · Decitabine (1) · Filgrastim (1) · Interleukin-2 (1) · KPT-9274 (1) · Mercaptopurine (1) · Metformin (1) · Vorinostat (1) · aldesleukin (1)
Memorial Sloan Kettering Cancer Center (2) · Xuzhou Medical University (2) · AB Science (1) · ARCE Therapeutics, Inc. (1) · Advesya SAS (1) · Affiliated Hospital to Academy of Military Medical Sciences (1) · Apollo Therapeutics Ltd (1) · AvenCell Europe GmbH (1) · Bio-Path Holdings, Inc. (1) · Caribou Biosciences, Inc. (1) · Centre Leon Berard (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · Medical College of Wisconsin (1) · Oryzon Genomics S.A. (1) · Peking University People's Hospital (1)
United States (13) · China (4) · France (4) · Germany (3) · Spain (3) · Australia (2) · Netherlands (2) · Belgium (1) · Greece (1) · Italy (1) · Lithuania (1) · Poland (1) · Romania (1) · Sweden (1) · United Kingdom (1)
Ai-Min Hui, MD, PhD (1) · Bayard Powell, MD (1) · Brian Shaffer, MD (1) · Christopher Bowden, MD (1) · Daniel Pollyea, MD (1) · Gail J Roboz, MD (1) · Giovanni Martinelli, MD, Prof (1) · Kailin Xu, M.D., Ph.D. (1) · Kailin Xu, MD.,PD. (1) · Liangding Hu, Docotr (1) · Manfred Klevesath, MD (1) · Mark Geyer, MD (1) · Matias Sanchez, MD (1) · Michael Burke, MD (1)
PMID 28280089, PMID 32822582, PMID 40864984
2019 (1), P30CA012197 (1)